Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Alemtuzumab and multiple sclerosis: therapeutic application.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
FDA approval announcement for ofatumumab
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Safety Study of Interferon Beta-1a for Acute Stroke
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Pericytes are required for blood-brain barrier integrity during embryogenesis.
Biogen Idec completes purchase of full rights and control of Tysabri®
Interferon beta for secondary progressive multiple sclerosis.
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Novel MS Drug Offers Good Functional Outcomes

Pages